$COO

Kurzius Lawrence Erik purchased $549K of COO

Kurzius Lawrence Erik purchased 10,000 shares of COOPER COMPANIES, INC. (COO) at $54.93 ($0.55M total) on 2026-09-16.

Original reporting
SEC EDGAR · Kurzius Lawrence Erik
Published Sep 17, 2026, 8:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 8:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$COO
Bullish
medium confidence
Mentioned
$COO
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$COOBullishMed
01

Why it matters

Director's purchase adds confidence but size is modest relative to market cap.

02

Market read

Primary insider buy; may influence short-term trading sentiment.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 6/10Novelty 6/10Timing: filing date 2026-09-16

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$COOBullishMedium confidence
Context

Director Kurzius purchased 10,000 shares at $54.93, increasing holdings to 31,099 shares.

Expected impact

Potential modest price lift in the near term as market absorbs insider buy signal.

Evidence & confidence

The purchase size (~$0.55M) is material for a director and is disclosed via a Form 4, a primary source.

Market effects

None significant beyond company-specific signal.

Limited to US equity markets where COO trades.

Low

Counterpoint

Insider purchases may be routine portfolio rebalancing, not a strong bullish indicator.

Key entities

  • Cooper Companies, Inc.

    Medical device and health solutions provider (ticker COO).

  • Kurzius Lawrence Erik

    Director of Cooper Companies.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$COOMedAI 8/10

A Failed Auction and a 15% Drop: Is Cooper Companies (COO) a Value Trap or a Bargain?

Cooper Companies (COO) ended its 9-month effort to sell CooperSurgical after bids undervalued the business, according to management. The stock dropped 15% to a 52-week low near $51 after a Q3 miss and cut outlook. The company's core contact lens business, CooperVision, posted flat organic revenue growth, contributing to the guidance cut. Management authorized a $1B share repurchase program, while Bank of America questioned the valuation. COO reported record Q3 free cash flow of $273M.

$COOMedAI 8/10

The Cooper Companies (COO) Faces Near-Term Pressure from Slowing Contact Lens Demand

The Cooper Companies (COO) lowered its fiscal 2026 profit and revenue forecasts due to weaker-than-expected contact lens demand, with adjusted EPS now expected at $4.51–$4.55 and revenue at $4.23–$4.25 billion. Q3 revenue was $1.07 billion, missing estimates, though adjusted EPS beat at $1.15. The company cited U.S. channel inventory reductions as a key factor and decided to retain CooperSurgical.